TAB3 and hepatocellular carcinoma: We demonstrated that hsa-miR-27b exerted a tumour-suppressor effect in HCC by targeting TAB3. Moreover, an oncolytic virus carrying hsa-miR-27b succeeded in suppressing tumour growth in a xenograft animal model, indicating the therapeutic role of hsa-miR-27b in patients with HCC.